---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-032195"
form_type: "8-K"
ticker: "EVFM"
cik: "0001618835"
company_name: "Evofem Biosciences, Inc."
filed_at: "2023-09-11T23:59:59+00:00"
generated_at: "2026-06-10T21:42:50.263675+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Evofem amends SPA: $97.5M notes repurchasable for up to $25M; default withdrawn

## Summary
- Investor withdraws March 2023 Notice of Default; waives all existing Events of Default.
- Notes no longer convertible into common stock, removing dilution from over 240M reserved shares.
- Evofem can repurchase Notes over 5 years for $14M–$25M, down from $97.5M outstanding balance.
- $1M upfront payment due Oct 1, 2023; quarterly cash payments up to 5% of global net product revenues.
- Notes continue to accrue 10% interest; failure to repurchase by Sept 8, 2028 allows full collection.

## SEC filing metadata
- accession: 0001493152-23-032195
- form_type: 8-K
- ticker: EVFM
- cik: 0001618835
- company_name: Evofem Biosciences, Inc.
- filed_at: 2023-09-11T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1618835/000149315223032195/0001493152-23-032195-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1618835/000149315223032195/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-032195
- JSON: https://secwatch.observer/filing/0001493152-23-032195.json
- Plain text: https://secwatch.observer/filing/0001493152-23-032195.txt

## Key facts
- Material Agreements
  Evofem Biosciences, Inc. amended Fourth Amendment with certain institutional investors (effective 2023-09-08).
  - Action: amendment
  - Agreement: equity purchase
  - Counterparty: certain institutional investors
  - Effective: 2023-09-08
  source text: On September 8, 2023 (“Effective Date”), Evofem Biosciences, Inc. (the “Company”), certain institutional investors (the “Purchasers”) and Baker Bros. Advisors LP as their designated agent (the “Designated Agent”) entered into a fourth amendment (the “Fourth Amendment”) to the Securities Purchase and Security Agreement by and among the Company, the Purchasers and the Designated Agent, dated as of April 23, 2020 (the “Agreement”), as amended, pursuant to which the Purchasers purchased certain convertible promissory notes (the “Notes”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1618835/000149315223032195/0001493152-23-032195-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.